Johnson & Johnson published interim results from its early-to-mid stage coronavirus vaccine clinical trial Friday, reporting that 99 percent of the participants between the ages of 18 and 55 developed neutralizing antibodies against the novel virus. The analysis also found that most of the side effects associated with the vaccine were mild and resolved within a matter of days. It wasn't clear, however, whether participants over 65 were well-protected since immune response results were available for only 15 people in the demographic. One of the key aspects of Johnson & Johnson's trial is that just a single dose produced a strong immune response in participants. Other companies developing vaccines like Moderna and Pfizer are using a two-dose approach. If Johnson & Johnson's recently-launched phase three trial, in which 60,000 volunteers will enroll across three continents, eventually proves the single dose is safe and effective, it could simplify distribution of the vaccine.

Scroll for 5 things you
need to know now